Compare Roundhill Magnificent Seven ETF (MAGS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Twist Bioscience Corp — how do they compare? Roundhill Magnificent Seven ETF trades at $73.73 (market cap $5.78B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Twist Bioscience Corp for 27 Days on average.
| MAGS | TWST | |
|---|---|---|
Market Cap | $5.78B | $10.08B |
Volume | 4,410,665 | 4,229,037 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $205.00 |
52-Week Low | $55.39 | $25.45 |
Typical Hold Time | 36 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $73.03, down 0.9% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides equal-weighted exposure to the Magnificent Seven tech stocks, though 2026 performance has been muted with a 2% year-to-date gain as the group faces increased competition and AI spending pressures. Recent news highlights both the long-term AI growth theme and near-term underperformance versus the broader market.
The outlook hinges on AI-driven earnings growth from its mega-cap holdings, but concentration risk and shifting investor sentiment pose challenges. Upside potential exists if the Magnificent Seven reassert leadership, while downside risks include prolonged sector rotation and margin compression from heavy capital expenditure.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
